Metabolomics Workbench : NIH Data Repository

Clustering data with hclust algorithm for Diabetic Microvascular Plasma/Tissue Lipidomics- Comparison (part II) (Study ST000672)

C18 NEGATIVE ION MODE (Analysis AN001030)

Metabolite	Structure	F1	F2	F3	F4	F5	F6	F7	F8
PA 38:1; [M-H]-@6.77	ME184543	0.15	2.33	0.27	2.40	0.11	0.58	0.09	1.66
CL 70:5; [M-2H](2-)@5.96	ME184482	0.37	2.21	0.16	2.27	0.27	0.37	0.19	1.76
PE 34:3; [M-H]-@5.95	ME184676	0.36	2.36	0.15	2.21	0.26	0.34	0.20	1.78
PE 33:2; [M-H]-@6.06	ME184668	0.28	1.47	0.11	2.42	0.23	0.45	0.20	2.05
plasmenyl-PE 33:1; [M-H]-@6.90	ME184878	0.11	1.75	0.06	2.19	0.09	0.80	0.13	2.23
plasmenyl-PE 38:1; [M-H]-@6.76	ME184894	0.06	1.92	0.19	2.08	0.07	0.94	0.20	2.04
PA 42:1; [M-H]-@8.49	ME184553	0.15	0.97	0.23	1.54	0.20	0.95	0.23	2.86
PC 46:2; [M-Ac-H]-@9.96	ME184656	0.17	1.22	0.12	1.88	0.09	1.31	0.09	2.51
lysoPE 18:1; [M-H]-@1.76	ME184858	0.21	1.31	0.03	1.82	0.15	1.11	0.04	2.71
lysoPE 22:1; [M-H]-@3.53	ME184868	0.07	1.46	0.04	1.84	0.07	0.95	0.05	2.79
lysoPE 22:4; [M-H]-@1.78	ME184869	0.20	1.47	0.40	1.15	0.20	2.40	0.36	1.96
lysoPE 24:4; [M-H]-@2.45	ME184874	0.12	1.90	0.22	1.36	0.12	2.22	0.18	2.06
plasmenyl-PE 40:2; [M-H]-@8.33	ME184903	0.08	1.91	0.10	1.72	0.10	1.85	0.28	1.93
PC 46:5; [M-Ac-H]-@8.89	ME184658	0.05	1.72	0.35	2.16	0.15	1.50	0.39	1.40
PS 46:6; [M-H]-@7.50	ME184850	0.12	1.61	0.36	2.34	0.12	1.64	0.43	1.13
plasmenyl-PE 38:2; [M-H]-@7.87	ME184896	0.26	1.75	0.45	1.58	0.28	1.54	0.70	1.36
PC 35:1; [M-Ac-H]-@7.21	ME184583	0.13	1.69	0.44	1.81	0.12	1.96	0.43	1.37
PC 42:4; [M-Ac-H]-@8.24	ME184636	0.14	1.88	0.47	1.85	0.17	1.64	0.41	1.36
PE 40:6; [M-H]-@5.95	ME184724	0.10	1.32	0.17	1.89	0.43	1.92	0.26	1.79
PE 37:1; [M-H]-@7.19	ME184696	NA	1.15	0.14	2.09	NA	1.38	0.18	1.32
PE 34:1; [M-H]-@5.26	ME184672	0.06	1.46	0.12	2.22	0.04	1.59	0.12	1.96
FFA(24:0)	ME184523	0.07	1.39	0.13	2.10	0.07	1.34	0.11	2.22
plasmenyl-PE 42:1; [M-H]-@9.11	ME184909	0.13	1.36	0.07	2.07	0.13	1.35	0.18	2.21
plasmenyl-PE 38:1; [M-H]-@8.24	ME184895	0.08	1.46	0.24	1.90	0.09	1.07	0.49	2.02
PC 34:1; [M-Ac-H]-@3.62	ME184575	0.06	1.50	0.65	2.05	0.08	1.17	0.28	1.62
PC 34:1; [M-Ac-H]-@4.47	ME184574	0.06	1.47	0.41	2.14	0.06	1.25	0.39	1.63
PC 46:6; [M-Ac-H]-@8.61	ME184659	0.09	0.91	0.74	2.16	0.23	1.46	0.76	1.00
PI 36:1; [M-H]-@6.12	ME184789	NA	0.55	0.39	2.19	NA	1.44	0.48	0.94
PC 32:3; [M-Ac-H]-@5.28	ME184568	0.38	0.95	NA	1.67	0.32	0.71	NA	1.16
PA 42:2; [M-H]-@8.66	ME184555	0.75	1.06	0.33	2.15	0.68	1.07	0.26	1.48
PS 34:3; [M-H]-@4.67	ME184808	0.67	1.24	0.37	2.00	0.60	1.23	0.46	1.30
plasmenyl-PE 34:3; [M-H]-@6.36	ME184884	NA	0.51	0.15	2.46	NA	0.59	0.16	1.68
PS 36:3; [M-H]-@5.94	ME184815	0.40	0.69	0.33	2.63	0.38	0.60	0.30	1.70
PA 44:1; [M-H]-@8.16	ME184556	0.27	1.16	0.21	2.70	0.26	0.69	0.21	1.69
PE 33:1; [M-H]-@6.56	ME184667	0.24	0.91	0.32	2.45	0.19	1.00	0.35	1.71
PC 38:1; [M-Ac-H]-@8.20	ME184602	0.09	0.46	0.31	2.39	0.08	1.28	0.38	1.97
PC 39:7; [M-Ac-H]-@6.06	ME184616	0.21	0.85	0.25	2.16	0.36	1.35	0.20	2.00
CL 72:3; [M-2H](2-)@6.05	ME184486	0.43	1.14	0.23	2.02	0.37	1.25	0.27	1.89
PE 35:2; [M-H]-@6.22	ME184681	0.41	1.14	0.22	2.17	0.23	1.00	0.20	2.02
PC 44:4; [M-Ac-H]-@8.79	ME184652	0.08	1.00	0.08	2.61	0.12	0.76	0.06	2.28
PC 32:2; [M-Ac-H]-@5.72	ME184567	0.17	1.01	0.14	2.28	0.16	1.15	0.15	2.18
plasmenyl-PE 34:2; [M-H]-@6.71	ME184883	0.20	1.01	0.16	2.20	0.13	0.98	0.22	2.25
MGDG 26:0; [M-H]-@5.95	ME184528	0.08	1.09	0.19	2.30	0.04	0.89	0.29	2.17
PA 36:3; [M-H]-@5.95	ME184541	0.09	0.97	0.28	2.39	0.11	0.92	0.26	2.02
PS 42:1; [M-H]-@17.88	ME184837	0.07	0.97	0.26	2.49	0.10	0.83	0.32	1.95
MGDG 37:4; [M-H]-@6.45	ME184530	0.21	0.84	0.75	1.60	0.19	1.48	0.80	1.50
PC 32:1; [M-Ac-H]-@6.21	ME184566	0.21	0.82	0.69	1.81	0.18	1.14	0.73	1.60
PA 34:0; [M-H]-@6.09	ME184533	0.15	0.78	1.03	2.14	0.11	0.94	0.31	1.52
PE 32:2; [M-H]-@5.69	ME184665	0.35	1.17	0.43	1.74	0.19	0.44	0.74	2.01
PC 28:0; [M-Ac-H]-@5.40	ME184560	0.17	0.49	0.56	2.15	0.21	0.81	0.78	1.66
PA 38:6; [M-H]-@5.62	ME184548	0.19	0.87	0.66	1.98	0.25	0.63	0.71	1.69
PE 34:0; [M-H]-@6.95	ME184670	0.34	0.87	0.68	2.00	0.32	0.50	0.73	1.57
PA 36:4; [M-H]-@5.74	ME184542	0.22	1.11	0.64	1.98	0.22	0.66	0.48	1.80
PE 38:1; [M-H]-@7.63	ME184701	0.12	0.97	0.50	2.01	0.23	0.80	0.67	1.76
PS 32:1; [M-H]-@5.03	ME184804	0.31	1.19	0.96	1.40	0.34	1.29	0.95	1.12
PC 33:0; [M-Ac-H]-@7.10	ME184569	0.48	1.05	1.16	1.28	0.39	1.41	1.03	0.87
plasmenyl-PE 38:5; [M-H]-@6.79	ME184900	0.43	0.97	1.04	1.27	0.35	1.63	0.99	1.00
PC 30:1; [M-Ac-H]-@5.54	ME184562	0.36	1.10	0.56	1.47	0.47	1.68	0.86	1.30
PE 38:4; [M-H]-@5.99	ME184708	0.28	1.58	0.74	1.23	0.33	1.41	1.02	1.21
PC 36:1; [M-Ac-H]-@7.48	ME184589	0.12	1.71	1.19	1.07	0.10	1.48	1.19	0.84
plasmenyl-PE 40:5; [M-H]-@7.40	ME184906	0.21	1.57	1.25	0.89	0.25	1.73	1.39	0.60
PC 35:0; [M-Ac-H]-@7.74	ME184582	0.23	1.99	0.70	1.38	0.16	1.82	1.00	0.81
PC 31:0; [M-Ac-H]-@6.45	ME184563	0.33	1.63	0.83	1.24	0.30	2.24	0.86	0.82
PC 34:0; [M-Ac-H]-@6.66	ME184572	0.17	1.51	0.75	1.32	0.13	2.02	0.84	1.17
PE 34:0; [M-H]-@5.78	ME184669	0.08	1.74	0.98	1.25	0.10	1.74	0.76	1.18
PG 38:4; [M-H]-@5.36	ME184768	1.12	1.73	NA	1.09	1.00	0.96	NA	0.51
PE 35:4; [M-H]-@6.06	ME184683	1.14	2.41	0.59	1.10	1.14	0.51	0.55	1.16
PE 39:7; [M-H]-@6.07	ME184717	0.96	1.44	0.64	1.43	1.07	0.52	0.93	1.01
PS 35:2; [M-H]-@5.50	ME184810	0.81	1.26	0.93	1.33	0.62	0.60	0.85	1.24
CL 70:7; [M-2H](2-)@5.42	ME184484	0.82	1.58	0.47	1.59	0.58	1.03	0.70	1.23
PE 34:4; [M-H]-@5.64	ME184677	0.66	2.22	0.55	1.37	0.58	0.90	0.72	1.18
PE 37:6; [M-H]-@5.96	ME184700	0.53	1.96	0.73	1.55	0.55	0.81	0.78	1.02
CL 72:5; [M-2H](2-)@6.14	ME184489	0.96	2.10	0.24	1.77	0.57	1.23	0.22	1.35
PE 38:3; [M-H]-@6.19	ME184705	0.40	2.10	0.35	1.83	0.25	1.02	0.44	1.49
PE 42:2; [M-H]-@8.49	ME184734	0.04	0.17	0.03	3.20	0.04	0.14	0.02	2.55
plasmenyl-PE 36:2; [M-H]-@7.30	ME184889	0.05	0.17	0.03	3.10	0.03	0.09	0.05	2.66
PE 43:1; [M-H]-@9.12	ME184740	0.01	0.14	0.02	3.19	0.00	0.11	0.01	2.65
PE 44:1; [M-H]-@9.31	ME184742	0.01	0.12	0.01	3.15	0.01	0.04	0.01	2.73
PA 36:1; [M-H]-@6.10	ME184539	0.03	0.07	0.15	3.28	0.01	0.03	0.03	2.47
PC 43:1; [M-Ac-H]-@9.62	ME184643	0.01	0.04	0.01	3.27	0.00	0.06	0.01	2.65
PC 42:1; [M-Ac-H]-@9.22	ME184631	0.00	0.01	0.01	3.27	0.00	0.01	0.01	2.70
PE 42:1; [M-H]-@8.90	ME184731	0.00	0.01	0.01	3.29	0.01	0.01	0.01	2.67
PC 41:1; [M-Ac-H]-@9.01	ME184629	0.00	0.05	0.01	3.41	0.01	0.03	0.02	2.51
PE 41:1; [M-H]-@8.67	ME184729	0.02	0.05	0.02	3.41	0.02	0.05	0.01	2.49
PC 40:1; [M-Ac-H]-@8.66	ME184618	0.01	0.03	0.02	3.37	0.01	0.04	0.02	2.56
CL 82:1; [M-2H](2-)@8.32	ME184509	0.02	0.06	0.02	3.34	0.02	0.04	0.03	2.54
PE 40:1; [M-H]-@8.43	ME184718	0.01	0.04	0.02	3.32	0.02	0.04	0.04	2.57
PC 40:1; [M-Ac-H]-@10.95	ME184619	0.01	0.22	0.02	2.99	0.01	0.13	0.01	2.80
plasmenyl-PE 36:1; [M-H]-@10.90	ME184887	0.01	0.06	0.02	2.86	0.01	0.12	0.03	2.99
PC 44:1; [M-Ac-H]-@10.33	ME184646	0.01	0.06	0.01	3.00	0.03	0.07	0.02	2.88
PC 44:1; [M-Ac-H]-@9.94	ME184645	0.01	0.03	0.01	2.96	0.01	0.04	0.01	2.98
plasmenyl-PE 36:1; [M-H]-@7.72	ME184888	0.05	0.15	0.11	2.95	0.03	0.13	0.17	2.59
PS 36:2; [M-H]-@5.81	ME184813	0.15	0.05	0.10	2.87	0.11	0.01	0.12	2.75
PC 42:3; [M-Ac-H]-@8.32	ME184635	0.05	0.76	0.06	2.99	0.05	1.02	0.07	1.94
PC 43:2; [M-Ac-H]-@9.05	ME184644	0.05	0.73	0.09	3.01	0.04	0.70	0.06	2.08
PA 42:1; [M-H]-@9.31	ME184554	0.02	0.22	0.13	3.47	0.02	0.24	0.20	1.95
PA 38:4; [M-H]-@5.74	ME184547	0.48	0.40	0.25	2.90	0.25	0.24	0.15	2.01
PS 35:1; [M-H]-@5.95	ME184809	0.22	0.52	0.20	2.82	0.18	0.19	0.26	2.16
PS 36:1; [M-H]-@6.27	ME184811	0.16	0.26	0.30	2.79	0.15	0.08	0.39	2.20
PE 35:1; [M-H]-@7.14	ME184679	0.16	0.80	0.22	2.70	0.20	0.46	0.23	2.04
PE 39:1; [M-H]-@8.26	ME184714	0.17	0.67	0.30	2.71	0.15	0.41	0.18	2.12
PE 44:3; [M-H]-@8.60	ME184747	0.28	0.41	0.15	2.96	0.26	0.65	0.14	1.94
plasmenyl-PE 36:3; [M-H]-@6.98	ME184890	0.17	0.39	0.29	2.93	0.12	0.47	0.29	1.91
PC 42:2; [M-Ac-H]-@8.71	ME184634	NA	0.13	0.02	2.86	NA	0.12	0.02	1.98
PC 44:2; [M-Ac-H]-@9.22	ME184650	NA	0.34	0.02	2.74	NA	0.16	0.01	1.98
plasmenyl-PE 34:1; [M-H]-@7.13	ME184880	0.11	0.44	0.15	2.58	0.08	0.13	0.22	2.67
PA 34:2; [M-H]-@5.78	ME184537	0.03	0.37	0.13	2.80	0.03	0.26	0.13	2.60
PE 40:2; [M-H]-@7.99	ME184720	0.06	0.42	0.12	2.92	0.10	0.31	0.13	2.38
PC 40:2; [M-Ac-H]-@8.17	ME184620	0.05	0.28	0.07	3.00	0.05	0.74	0.09	2.28
PC 44:3; [M-Ac-H]-@8.84	ME184651	0.06	0.59	0.03	2.99	0.04	0.48	0.02	2.38
PA 34:1; [M-H]-@5.63	ME184535	0.07	0.42	0.28	2.93	0.04	0.47	0.10	2.18
PE 31:1; [M-H]-@5.92	ME184662	0.09	0.56	0.18	2.75	0.06	0.57	0.13	2.31
PA 34:1; [M-H]-@6.21	ME184536	0.02	0.17	0.29	3.02	0.03	0.15	0.20	2.30
PA 38:2; [M-H]-@6.16	ME184544	0.13	0.35	0.10	3.09	0.09	0.30	0.06	2.31
PA 36:2; [M-H]-@5.74	ME184540	0.30	0.29	0.10	3.05	0.08	0.26	0.07	2.33
PA 38:3; [M-H]-@5.87	ME184545	0.30	0.34	0.13	3.04	0.14	0.35	0.06	2.22
PC 39:1; [M-Ac-H]-@8.48	ME184611	0.02	0.27	0.03	3.23	0.02	0.29	0.04	2.40
PE 44:2; [M-H]-@8.92	ME184746	0.05	0.14	0.04	3.14	0.05	0.33	0.02	2.51
plasmenyl-PE 36:1; [M-H]-@6.17	ME184886	0.01	0.31	0.04	2.58	0.01	0.37	0.04	3.00
plasmenyl-PE 34:1; [M-H]-@5.94	ME184881	0.05	0.36	0.09	2.21	0.02	0.21	0.14	3.23
plasmenyl-PE 34:1; [M-H]-@8.79	ME184882	0.06	0.21	0.11	2.38	0.05	0.14	0.17	3.12
PC 46:1; [M-Ac-H]-@10.69	ME184655	0.04	0.81	0.05	2.23	0.03	0.65	0.08	2.87
plasmenyl-PE 40:1; [M-H]-@8.70	ME184902	0.02	0.64	0.07	2.17	0.04	0.75	0.14	2.90
plasmenyl-PE 32:1; [M-H]-@6.58	ME184877	0.18	0.70	0.23	2.22	0.10	0.47	0.33	2.49
lysoPE 24:1; [M-H]-@4.42	ME184873	0.14	0.57	0.19	2.34	0.05	0.96	0.15	2.45
PA 32:1; [M-H]-@5.97	ME184531	0.05	0.64	0.16	2.32	0.02	0.88	0.23	2.49
PE 44:4; [M-H]-@8.59	ME184748	0.43	NA	NA	1.31	0.55	NA	NA	1.20
PS 40:6; [M-H]-@6.06	ME184831	0.96	0.16	NA	1.88	1.15	0.07	NA	0.95
PA 40:5; [M-H]-@5.82	ME184551	0.83	NA	0.83	1.57	0.48	NA	0.80	1.15
PA 40:6; [M-H]-@5.59	ME184552	1.29	0.21	1.28	1.56	0.67	0.35	0.92	0.99
PE 40:10; [M-H]-@5.11	ME184719	1.32	0.33	0.78	1.91	0.70	0.27	0.72	1.28
PS 40:5; [M-H]-@5.94	ME184830	0.19	0.07	1.31	1.78	0.20	0.04	1.65	1.01
PS 40:7; [M-H]-@5.22	ME184833	0.28	0.13	1.01	2.41	0.26	0.09	1.08	1.11
PS 38:3; [M-H]-@6.08	ME184821	0.36	0.13	1.13	1.76	0.39	0.06	1.18	1.46
PE 36:1; [M-H]-@7.44	ME184686	0.20	0.41	1.14	1.79	0.20	0.13	1.14	1.46
PS 40:7; [M-H]-@5.91	ME184834	0.19	0.50	1.09	1.93	0.18	0.30	1.09	1.31
PE 32:1; [M-H]-@6.21	ME184664	0.23	0.49	0.66	1.91	0.20	0.24	1.23	1.62
PS 42:7; [M-H]-@5.91	ME184842	0.05	0.39	0.95	2.17	0.11	0.27	0.85	1.62
PS 34:2; [M-H]-@5.20	ME184807	1.10	0.19	0.43	2.33	0.69	0.18	0.41	1.75
PS 38:1; [M-H]-@6.91	ME184819	NA	NA	0.16	2.02	NA	NA	0.31	1.51
PC 30:0; [M-Ac-H]-@6.06	ME184561	0.18	NA	0.59	1.79	0.20	NA	0.68	1.74
PE 38:1; [M-H]-@7.98	ME184702	0.10	NA	0.46	2.18	0.21	NA	0.61	1.60
PS 38:2; [M-H]-@6.37	ME184820	0.05	NA	0.42	2.19	0.06	NA	0.48	1.85
PS 36:3; [M-H]-@5.35	ME184814	0.47	0.30	0.45	2.87	0.28	0.16	0.41	1.67
PS 38:5; [M-H]-@5.97	ME184824	0.35	0.33	0.60	2.19	0.43	0.16	0.67	1.90
PE 34:1; [M-H]-@6.83	ME184673	0.19	0.62	0.41	2.39	0.17	0.35	0.50	2.04
PS 34:1; [M-H]-@5.74	ME184806	0.42	0.44	0.41	2.40	0.28	0.13	0.46	2.10
PA 33:0; [M-H]-@5.94	ME184532	0.02	0.48	1.16	0.55	0.02	0.77	3.12	0.53
PA 39:6; [M-H]-@5.48	ME184549	0.18	0.31	1.25	0.50	0.10	0.26	3.45	0.39
PE 42:11; [M-H]-@5.41	ME184733	0.47	0.10	2.30	0.76	0.23	0.05	1.88	0.64
PE 44:10; [M-H]-@6.36	ME184743	NA	0.08	2.30	0.32	NA	0.06	2.04	0.27
PE 42:9; [M-H]-@6.05	ME184739	0.28	0.10	2.63	0.53	0.25	0.06	2.11	0.38
PS 42:10; [M-H]-@4.69	ME184838	0.11	0.11	2.55	0.45	0.08	0.37	2.28	0.38
PE 42:8; [M-H]-@6.53	ME184738	0.10	0.23	2.34	0.49	0.14	0.14	2.48	0.38
PI 34:1; [M-H]-@5.57	ME184786	0.15	0.15	2.29	0.58	0.17	0.18	2.35	0.46
PI 40:7; [M-H]-@5.15	ME184802	0.04	0.11	2.63	0.07	0.04	0.16	3.07	0.06
PS 44:11; [M-H]-@4.77	ME184846	0.00	0.01	2.81	0.24	0.00	0.02	2.76	0.17
PS 44:12; [M-H]-@4.56	ME184847	0.00	0.01	2.86	0.09	0.00	0.01	2.96	0.08
PC 44:12; [M-Ac-H]-@5.64	ME184649	0.08	0.04	2.93	0.03	0.03	0.08	2.90	0.03
PE 44:12; [M-H]-@5.59	ME184745	0.04	0.01	2.95	0.06	0.03	0.01	2.91	0.04
PS 40:6; [M-H]-@5.74	ME184832	0.16	0.03	2.58	0.31	0.19	0.01	2.76	0.16
PC 44:11; [M-Ac-H]-@5.90	ME184648	0.11	0.19	2.75	0.12	0.05	0.24	2.72	0.12
PC 48:6; [M-Ac-H]-@8.87	ME184660	0.01	0.21	2.50	0.26	0.01	0.31	2.82	0.15
PG 36:4; [M-H]-@5.30	ME184763	0.21	0.59	2.58	0.27	0.20	0.33	2.25	0.24
PI 42:10; [M-H]-@4.59	ME184803	0.03	0.60	2.66	0.15	0.03	0.35	2.57	0.12
PA 44:12; [M-H]-@5.05	ME184557	0.03	0.32	2.97	0.14	0.04	0.40	2.42	0.07
PS 42:11; [M-H]-@4.25	ME184839	0.04	0.48	2.82	0.10	0.03	0.54	2.46	0.07
PA 35:1; [M-H]-@5.97	ME184538	0.01	0.07	0.96	1.28	0.01	0.03	2.38	1.33
PS 40:8; [M-H]-@4.75	ME184835	0.67	0.26	1.42	1.58	0.42	0.59	1.54	0.50
PE 44:11; [M-H]-@5.95	ME184744	0.04	NA	1.82	0.83	0.05	NA	1.63	0.68
PS 40:4; [M-H]-@6.30	ME184829	0.13	NA	1.66	0.71	0.15	NA	1.80	0.69
PC 32:0; [M-Ac-H]-@3.84	ME184565	0.30	NA	1.85	0.64	0.67	NA	1.66	0.37
PE 42:10; [M-H]-@5.70	ME184732	0.77	0.17	1.95	1.00	0.57	0.09	1.46	0.79
PE 42:4; [M-H]-@8.10	ME184735	0.62	NA	1.73	0.79	0.60	NA	1.28	0.60
PS 38:5; [M-H]-@5.38	ME184825	0.94	0.11	1.53	1.01	0.83	0.08	1.51	0.97
PS 38:4; [M-H]-@5.82	ME184823	0.99	0.03	1.31	1.24	0.92	0.03	1.22	1.24
PS 38:4; [M-H]-@6.07	ME184822	0.99	0.03	1.31	1.24	0.92	0.02	1.22	1.24
PG 38:6; [M-H]-@5.19	ME184772	0.32	0.17	1.56	1.25	0.68	0.16	1.93	0.59
PG 38:5; [M-H]-@5.34	ME184770	0.57	0.52	1.31	1.26	0.55	0.19	1.49	1.02
PE 42:7; [M-H]-@7.00	ME184737	0.29	NA	1.25	1.00	0.29	NA	1.70	0.77
CL 78:3; [M-2H](2-)@7.50	ME184507	0.45	NA	1.12	1.01	0.67	NA	1.38	0.94
PE 38:2; [M-H]-@7.45	ME184703	0.46	NA	1.20	1.00	0.62	NA	1.36	0.91
PE 38:2; [M-H]-@7.58	ME184704	0.46	NA	1.20	1.00	0.62	NA	1.36	0.91
PE 40:9; [M-H]-@5.52	ME184728	1.66	0.30	2.13	0.75	0.70	0.14	1.40	0.33
CL 76:10; [M-2H](2-)@9.14	ME184499	1.05	NA	1.73	0.12	1.36	NA	1.85	0.09
CL 78:12; [M-2H](2-)@9.00	ME184505	0.82	NA	1.82	0.15	1.33	NA	1.82	0.13
PG 34:1; [M-H]-@5.70	ME184754	1.18	0.24	2.16	0.22	0.91	0.12	2.18	0.21
PC 32:0; [M-Ac-H]-@6.71	ME184564	0.74	0.39	1.98	0.47	0.73	0.52	2.05	0.30
PE 40:4; [M-H]-@7.47	ME184722	0.62	0.31	2.31	0.30	0.57	0.25	2.26	0.25
PE 38:5; [M-H]-@5.64	ME184710	1.03	NA	1.02	NA	1.13	NA	0.90	NA
PE 42:6; [M-H]-@7.51	ME184736	0.10	NA	1.47	NA	0.17	NA	1.39	NA
plasmenyl-PE 38:0; [M-H]-@8.71	ME184893	0.07	NA	1.31	NA	0.12	NA	1.60	NA
PG 36:0; [M-H]-@6.80	ME184757	0.34	NA	1.26	NA	0.52	NA	1.30	NA
plasmenyl-PE 36:0; [M-H]-@8.25	ME184885	0.42	NA	1.01	NA	0.30	NA	1.63	NA
PG 40:7; [M-H]-@5.32	ME184776	0.41	1.15	1.57	0.44	1.77	1.12	1.50	0.26
PG 40:7; [M-H]-@4.95	ME184775	1.96	0.55	1.16	0.64	2.31	0.65	0.96	0.51
PG 40:6; [M-H]-@5.14	ME184774	1.66	0.65	1.14	0.74	1.82	1.19	0.92	0.55
PG 44:10; [M-H]-@4.98	ME184783	1.23	0.79	1.20	0.72	1.76	1.40	1.06	0.43
PE 40:8; [M-H]-@5.94	ME184727	1.25	0.75	1.11	1.29	0.95	0.13	1.16	0.90
PS 37:4; [M-H]-@5.55	ME184818	1.23	0.60	1.21	0.91	1.44	0.42	1.21	0.82
PA 38:4; [M-H]-@6.36	ME184546	0.99	0.49	1.60	0.90	0.69	0.96	1.18	0.75
PG 42:10; [M-H]-@4.46	ME184779	1.21	0.41	1.72	0.63	1.46	0.79	1.33	0.39
PG 36:3; [M-H]-@5.21	ME184761	2.01	1.34	1.29	0.39	0.84	0.50	1.39	0.59
PG 32:1; [M-H]-@5.13	ME184751	1.15	1.10	1.41	0.45	1.22	0.72	1.55	0.49
PG 42:9; [M-H]-@4.70	ME184782	1.41	1.03	1.56	0.50	1.47	0.50	1.40	0.34
CL 70:4; [M-2H](2-)@9.38	ME184481	1.52	1.27	1.71	0.18	0.98	0.67	1.74	0.15
CL 70:5; [M-2H](2-)@9.21	ME184483	1.55	1.57	1.53	0.20	1.31	0.84	1.47	0.17
CL 72:5; [M-2H](2-)@9.44	ME184488	1.96	0.63	1.53	0.37	1.28	0.29	1.79	0.23
PE 36:6; [M-H]-@5.46	ME184695	1.33	0.63	1.25	0.54	1.36	0.40	2.03	0.32
PG 32:0; [M-H]-@5.65	ME184750	0.83	0.54	1.45	0.45	1.78	0.26	2.00	0.39
plasmenyl-PE 38:6; [M-H]-@6.51	ME184901	0.72	1.39	1.41	0.39	0.86	1.86	1.50	0.29
PC 42:8; [M-Ac-H]-@6.53	ME184641	0.29	0.92	1.69	0.55	0.18	1.80	1.77	0.40
PS 42:9; [M-H]-@4.94	ME184844	0.09	0.87	1.76	0.45	0.17	2.02	1.95	0.27
PC 36:0; [M-Ac-H]-@8.18	ME184588	0.17	1.81	1.51	0.43	0.14	2.08	1.62	0.34
plasmenyl-PE 40:4; [M-H]-@7.70	ME184905	0.21	1.57	1.71	0.46	0.18	1.31	1.70	0.49
PG 36:5; [M-H]-@4.92	ME184764	0.41	1.72	1.73	0.30	0.49	0.83	2.03	0.20
plasmenyl-PE 34:0; [M-H]-@7.54	ME184879	0.32	2.03	1.81	0.21	0.18	0.51	2.32	0.14
PC 24:6; [M-Ac-H]-@1.39	ME184559	0.37	1.29	1.67	0.09	0.54	1.20	2.45	0.09
PE 36:0; [M-H]-@7.92	ME184684	0.27	1.54	2.01	0.05	0.39	1.51	2.05	0.03
PS 44:10; [M-H]-@5.21	ME184845	0.15	0.39	1.81	0.78	0.27	0.67	2.01	0.66
PG 38:4; [M-H]-@5.94	ME184769	0.17	0.91	1.83	0.61	0.19	0.21	2.34	0.48
PS 41:6; [M-H]-@6.05	ME184836	0.23	0.79	1.48	0.59	0.53	0.50	2.42	0.48
CL 72:1; [M-2H](2-)@8.01	ME184485	0.25	0.84	1.44	0.85	0.29	0.33	2.09	0.76
PE 30:0; [M-H]-@6.07	ME184661	0.21	0.97	1.18	0.72	0.46	0.50	2.25	0.77
plasmenyl-PE 40:6; [M-H]-@7.11	ME184907	0.49	0.96	1.77	0.55	0.61	1.00	1.86	0.30
plasmenyl-PE 40:6; [M-H]-@7.26	ME184908	0.49	0.96	1.77	0.55	0.61	1.00	1.86	0.30
PC 42:6; [M-Ac-H]-@7.12	ME184638	0.21	1.02	1.98	0.45	0.37	1.09	2.02	0.21
PC 44:10; [M-Ac-H]-@6.11	ME184647	0.48	1.25	2.13	0.35	0.45	1.00	1.78	0.16
plasmenyl-PE 36:4; [M-H]-@6.64	ME184891	1.07	0.67	2.15	0.23	0.66	0.72	1.84	0.23
plasmenyl-PE 38:4; [M-H]-@7.21	ME184898	0.93	1.02	1.86	0.48	0.62	0.76	1.60	0.40
plasmenyl-PE 38:4; [M-H]-@7.38	ME184899	0.95	1.03	1.88	0.48	0.63	0.60	1.62	0.41
PE 40:5; [M-H]-@7.12	ME184723	0.31	1.32	2.02	0.32	0.38	0.44	2.19	0.24
PE 40:6; [M-H]-@6.85	ME184725	0.19	1.11	2.35	0.12	0.31	0.27	2.50	0.10
CL 76:9; [M-2H](2-)@9.31	ME184504	0.69	0.66	1.94	0.10	0.86	0.63	2.45	0.09
PE 32:0; [M-H]-@6.75	ME184663	0.63	0.97	1.98	0.11	0.76	0.65	2.23	0.18
CL 72:4; [M-2H](2-)@9.60	ME184487	0.41	0.78	2.09	0.28	0.28	0.52	2.37	0.26
PI 38:6; [M-H]-@4.99	ME184797	0.18	0.52	2.06	0.38	0.35	0.94	2.22	0.36
PE 40:3; [M-H]-@7.61	ME184721	0.53	1.81	1.58	0.65	0.44	0.71	1.53	0.50
PE 38:6; [M-H]-@6.14	ME184711	1.08	2.11	1.49	0.37	0.60	0.61	1.67	0.26
PE 40:7; [M-H]-@6.36	ME184726	0.99	2.04	1.50	0.54	0.97	0.55	1.39	0.30
PG 36:3; [M-H]-@5.51	ME184760	0.93	1.18	1.14	NA	0.74	0.41	1.23	NA
PE 41:6; [M-H]-@7.10	ME184730	0.09	1.20	1.12	NA	0.27	1.01	1.59	NA
PG 36:1; [M-H]-@6.35	ME184758	0.27	1.47	1.26	NA	0.30	0.92	1.26	NA
PG 36:4; [M-H]-@4.75	ME184762	4.55	1.27	0.27	0.63	1.08	1.15	0.34	0.72
PG 40:8; [M-H]-@4.51	ME184777	2.65	0.81	0.86	0.77	2.27	0.64	0.78	0.42
PS 38:6; [M-H]-@5.06	ME184826	2.91	0.27	0.89	0.85	2.62	0.21	0.84	0.41
PG 42:11; [M-H]-@4.06	ME184780	2.32	1.23	0.88	0.37	2.75	0.93	0.81	0.32
CL 74:7; [M-2H](2-)@9.32	ME184495	2.73	0.77	1.18	0.20	2.49	0.35	1.31	0.14
CL 74:8; [M-2H](2-)@9.08	ME184496	2.59	0.71	1.26	0.10	2.48	0.77	1.27	0.09
CL 74:9; [M-2H](2-)@8.98	ME184498	2.32	0.77	1.23	0.18	2.68	0.52	1.36	0.09
PG 44:11; [M-H]-@4.62	ME184784	1.52	0.35	1.55	0.37	2.45	0.43	1.50	0.21
PG 44:12; [M-H]-@4.34	ME184785	1.69	0.17	1.59	0.24	2.64	0.22	1.66	0.15
CL 76:11; [M-2H](2-)@8.98	ME184500	2.17	NA	1.20	0.14	2.60	NA	1.16	0.12
CL 76:12; [M-2H](2-)@8.77	ME184501	2.25	NA	0.82	0.16	3.40	NA	1.00	0.20
PC 34:2; [M-Ac-H]-@5.99	ME184578	3.25	NA	NA	0.10	2.35	NA	NA	0.10
PS 36:5; [M-H]-@4.80	ME184817	3.67	0.59	0.61	0.47	3.66	0.54	0.47	0.22
PS 36:4; [M-H]-@5.18	ME184816	3.85	0.29	0.84	0.71	2.54	0.18	0.59	0.43
CL 72:6; [M-2H](2-)@9.25	ME184490	3.36	0.39	0.91	0.30	2.84	0.57	0.96	0.25
CL 72:7; [M-2H](2-)@9.04	ME184491	3.55	0.33	0.90	0.26	3.23	0.28	0.96	0.19
CL 72:8; [M-2H](2-)@8.84	ME184492	3.72	0.45	0.93	0.23	3.05	0.40	0.76	0.28
PG 34:3; [M-H]-@4.66	ME184756	2.10	1.18	0.67	0.48	0.97	2.38	0.84	0.69
PG 38:6; [M-H]-@4.64	ME184771	3.02	1.77	0.35	0.80	1.74	1.38	0.32	0.58
CL 80:13; [M-2H](2-)@5.50	ME184508	2.31	0.99	0.75	0.68	1.96	1.43	0.80	0.42
PG 38:7; [M-H]-@4.24	ME184773	2.04	1.38	0.56	0.80	2.04	2.22	0.31	0.47
PG 36:2; [M-H]-@5.88	ME184759	0.85	3.16	1.01	0.60	0.64	0.60	1.20	0.57
PG 34:2; [M-H]-@5.27	ME184755	2.46	2.38	0.75	0.30	1.98	0.91	0.81	0.27
PE 38:4; [M-H]-@6.91	ME184707	2.01	3.06	0.88	0.24	1.91	0.62	0.89	0.20
CL 74:9; [M-2H](2-)@5.69	ME184497	1.93	2.86	0.59	0.45	2.09	0.71	0.80	0.36
PE 36:5; [M-H]-@5.90	ME184694	1.89	2.95	0.60	0.40	2.17	0.62	0.85	0.33
CL 78:13; [M-2H](2-)@5.82	ME184506	1.65	2.66	0.86	0.73	1.58	0.75	0.63	0.46
PE 38:7; [M-H]-@5.65	ME184712	1.63	2.55	0.84	0.76	1.49	0.64	0.70	0.55
PE 38:3; [M-H]-@7.29	ME184706	1.23	2.58	1.05	0.35	1.35	0.86	1.29	0.30
PE 38:5; [M-H]-@6.50	ME184709	1.52	3.10	1.02	0.35	1.14	0.86	0.97	0.35
FFA(22:1)	ME184520	3.04	1.97	0.03	0.16	2.79	3.44	0.03	0.17
PC 20:0; [M-Ac-H]-@2.03	ME184558	1.11	2.41	0.19	0.50	4.16	1.89	0.20	0.33
PC 38:5; [M-Ac-H]-@5.35	ME184607	1.24	2.67	0.19	0.21	4.35	2.45	0.13	0.12
PI 39:4; [M-H]-@6.06	ME184798	0.05	2.40	0.12	0.42	0.12	7.07	0.21	0.44
FFA(18:2)	ME184515	0.22	8.28	0.01	0.13	0.11	2.96	0.02	0.06
lysoPE 18:2; [M-H]-@1.31	ME184859	0.08	7.04	0.01	0.08	0.05	4.48	0.01	0.08
PC 35:2; [M-Ac-H]-@6.70	ME184584	0.12	7.22	0.05	0.18	0.08	3.78	0.06	0.11
PE 36:4; [M-H]-@4.57	ME184693	0.03	7.04	0.16	0.07	0.05	3.98	0.12	0.10
lysoPE 20:4; [M-H]-@1.27	ME184865	0.25	6.78	0.08	0.07	0.28	4.15	0.06	0.07
PC 36:2; [M-Ac-H]-@6.98	ME184591	0.16	6.53	0.12	0.19	0.11	4.03	0.12	0.15
PE 36:3; [M-H]-@4.98	ME184690	0.16	6.44	0.12	0.34	0.16	3.32	0.12	0.39
FFA(18:1)	ME184514	0.21	7.58	0.06	0.18	0.10	3.27	0.08	0.10
FFA(20:2)	ME184518	0.43	7.00	0.11	0.15	0.25	3.33	0.16	0.08
PC 37:4; [M-Ac-H]-@6.65	ME184600	0.20	7.13	0.12	0.22	0.17	3.30	0.09	0.17
FFA(22:2)	ME184521	0.95	3.86	0.05	0.21	0.75	5.46	0.07	0.16
PC 34:2; [M-Ac-H]-@5.19	ME184577	0.17	3.77	0.12	0.18	0.08	6.88	0.07	0.18
lysoPE 22:5; [M-H]-@1.46	ME184870	0.11	4.32	0.08	0.24	0.14	6.15	0.09	0.23
PC 37:2; [M-Ac-H]-@7.40	ME184598	0.08	4.04	0.10	0.51	0.10	5.70	0.09	0.35
lysoPE 20:5; [M-H]-@1.00	ME184866	0.21	6.35	0.06	0.03	0.32	4.81	0.04	0.02
PC 34:2; [M-Ac-H]-@6.37	ME184576	0.24	5.86	0.09	0.16	0.16	4.84	0.09	0.12
PC 36:3; [M-Ac-H]-@6.55	ME184592	0.33	5.95	0.15	0.13	0.22	4.43	0.15	0.11
PE 34:0; [M-H]-@7.33	ME184671	0.11	5.25	0.45	0.01	0.11	4.79	0.41	0.00
lysoPE 20:3; [M-H]-@1.61	ME184864	0.09	5.80	0.07	0.11	0.13	5.26	0.06	0.12
FFA(20:1)	ME184517	0.23	5.40	0.07	0.13	0.16	5.44	0.09	0.10
lysoPE 22:6; [M-H]-@1.22	ME184871	0.13	5.38	0.15	0.07	0.29	5.14	0.26	0.06
PG 34:0; [M-H]-@6.15	ME184753	0.03	5.40	0.32	0.05	0.02	5.20	0.28	0.03
PC 39:4; [M-Ac-H]-@7.34	ME184612	0.17	4.84	0.15	0.22	0.20	5.54	0.10	0.15
PC 36:2; [M-Ac-H]-@10.90	ME184590	0.21	4.53	0.10	0.39	0.09	5.29	0.09	0.36
PI 37:4; [M-H]-@5.42	ME184793	0.08	4.54	0.26	0.27	0.08	5.22	0.30	0.20
PC 33:2; [M-Ac-H]-@6.06	ME184571	0.12	4.61	0.07	0.61	0.09	4.59	0.09	0.52
lysoPE 16:0; [M-H]-@1.62	ME184852	0.44	4.85	0.09	0.32	0.42	4.57	0.10	0.36
FFA(22:3)	ME184522	0.38	4.48	0.22	0.21	0.43	4.88	0.29	0.18
PC 36:5; [M-Ac-H]-@5.76	ME184595	0.27	4.35	0.19	0.42	0.38	4.78	0.24	0.26
lysoPE 20:2; [M-H]-@2.03	ME184863	0.27	4.07	0.23	0.43	0.39	4.18	0.22	0.67
PC 35:3; [M-Ac-H]-@6.22	ME184585	0.28	3.93	0.53	0.21	0.54	4.40	0.47	0.22
FFA(16:0)	ME184512	0.14	4.21	0.57	0.39	0.13	4.03	0.52	0.27
FFA(18:0)	ME184513	0.14	4.23	0.58	0.37	0.12	4.06	0.52	0.25
CerP 34:2; [M-H]-@5.33	ME184511	0.58	4.35	0.34	0.38	0.43	4.21	0.23	0.27
PC 38:5; [M-Ac-H]-@6.49	ME184606	0.41	4.31	0.46	0.30	0.34	4.13	0.42	0.22
PS 42:4; [M-H]-@6.72	ME184841	0.40	4.47	0.35	0.31	0.34	4.28	0.36	0.23
PI 36:3; [M-H]-@5.28	ME184791	0.22	3.45	0.41	0.49	0.21	4.33	0.50	0.49
FFA(20:0)	ME184516	0.19	3.91	0.49	0.31	0.17	4.83	0.42	0.23
lysoPE 19:0; [M-H]-@2.94	ME184860	0.22	3.44	0.49	0.34	0.25	5.05	0.43	0.26
PC 36:4; [M-Ac-H]-@11.02	ME184594	0.40	6.78	0.32	0.29	0.29	2.14	0.25	0.33
CL 70:1; [M-2H](2-)@6.22	ME184480	0.50	5.93	0.20	0.71	0.28	1.79	0.22	0.63
PE 34:2; [M-H]-@6.36	ME184675	0.50	6.19	0.15	0.68	0.35	1.86	0.20	0.53
PC 36:4; [M-Ac-H]-@6.23	ME184593	0.48	5.49	0.33	0.21	0.39	3.64	0.29	0.18
lysoPE 18:0; [M-H]-@2.41	ME184857	0.66	5.57	0.21	0.21	0.86	3.25	0.24	0.19
PC 35:4; [M-Ac-H]-@5.87	ME184586	0.38	5.73	0.28	0.39	0.39	3.05	0.26	0.30
CL 76:3; [M-2H](2-)@7.12	ME184502	0.60	5.60	0.17	0.58	0.57	2.49	0.17	0.45
PC 38:4; [M-Ac-H]-@6.92	ME184605	0.30	5.94	0.51	0.25	0.27	2.57	0.51	0.20
PC 45:4; [M-Ac-H]-@9.03	ME184654	0.08	4.63	0.11	1.11	0.06	2.69	0.08	0.97
PE 36:2; [M-H]-@5.40	ME184688	0.16	4.17	0.07	1.08	0.14	2.62	0.06	1.24
PC 40:5; [M-Ac-H]-@7.21	ME184623	0.24	4.35	NA	0.17	0.29	2.54	NA	0.12
PE 36:2; [M-H]-@6.23	ME184687	0.74	4.99	0.16	0.68	0.42	2.69	0.12	0.62
PE 37:2; [M-H]-@7.25	ME184697	0.61	4.58	0.21	0.68	0.70	2.88	0.21	0.52
PC 40:9; [M-Ac-H]-@5.46	ME184628	0.17	4.57	0.54	0.53	0.19	2.79	0.61	0.46
PI 38:4; [M-H]-@5.71	ME184795	0.17	4.42	0.50	0.51	0.18	3.14	0.58	0.46
lysoPE 17:0; [M-H]-@1.98	ME184855	0.40	4.49	0.42	0.45	0.48	3.46	0.34	0.37
PC 39:6; [M-Ac-H]-@6.58	ME184614	0.34	4.10	0.48	0.59	0.32	3.55	0.48	0.30
PC 34:3; [M-Ac-H]-@5.89	ME184579	0.23	4.79	0.18	0.55	0.18	3.98	0.20	0.47
PC 37:3; [M-Ac-H]-@6.90	ME184599	0.15	5.35	0.14	0.90	0.19	3.52	0.09	0.27
PC 38:3; [M-Ac-H]-@7.32	ME184604	0.15	4.83	0.21	0.78	0.20	3.24	0.19	0.61
PS 42:2; [M-H]-@7.44	ME184840	0.15	4.86	0.19	0.78	0.20	3.25	0.18	0.61
PA 34:0; [M-H]-@6.94	ME184534	0.06	4.84	1.03	0.18	0.08	2.62	0.91	0.07
PE 35:0; [M-H]-@7.59	ME184678	0.25	3.76	0.74	0.69	0.32	2.19	0.76	0.55
plasmenyl-PE 30:0; [M-H]-@6.48	ME184875	0.56	3.83	0.41	0.68	0.18	2.34	0.60	0.87
Arachidonic acid	ME184478	0.64	4.14	0.67	0.45	0.59	2.15	0.80	0.31
PE 33:0; [M-H]-@7.06	ME184666	0.23	4.40	0.60	0.64	0.34	2.16	0.64	0.56
PE 37:4; [M-H]-@6.65	ME184698	1.94	4.70	0.28	0.29	1.78	1.22	0.27	0.34
PE 39:4; [M-H]-@7.22	ME184715	1.23	3.79	0.33	0.25	2.48	2.31	0.39	0.13
PE 35:3; [M-H]-@6.24	ME184682	1.37	3.24	0.26	NA	0.72	1.59	0.28	NA
MGDG 34:1; [M-H]-@7.09	ME184529	0.56	4.10	0.44	NA	0.24	1.73	0.25	NA
PC 39:6; [M-Ac-H]-@5.54	ME184615	0.57	3.56	0.25	NA	0.97	1.98	0.21	NA
CL 68:1; [M-2H](2-)@7.30	ME184479	0.73	4.69	0.84	0.38	0.58	1.13	0.98	0.23
PE 35:2; [M-H]-@6.71	ME184680	0.40	5.16	0.07	1.23	0.28	1.32	0.07	1.04
CL 74:5; [M-2H](2-)@6.42	ME184494	1.19	4.85	0.28	0.85	0.83	1.03	0.28	0.64
PE 36:3; [M-H]-@6.20	ME184691	1.21	5.05	0.25	0.87	0.75	0.90	0.26	0.66
PE 36:3; [M-H]-@6.55	ME184692	1.21	5.05	0.25	0.87	0.75	0.90	0.26	0.66
PC 42:6; [M-Ac-H]-@7.57	ME184639	0.10	0.73	1.37	0.27	0.22	4.62	1.40	0.12
PG 33:0; [M-H]-@5.93	ME184752	0.20	3.02	0.59	1.34	0.19	1.49	0.57	1.05
PE 36:1; [M-H]-@6.81	ME184685	0.30	3.26	0.22	1.51	0.26	1.26	0.23	1.50
CL 74:3; [M-2H](2-)@6.98	ME184493	0.30	3.48	0.09	1.67	0.27	0.96	0.11	1.63
PE 36:2; [M-H]-@6.94	ME184689	0.30	3.48	0.09	1.67	0.26	0.86	0.12	1.67
PG 36:5; [M-H]-@4.18	ME184765	2.21	3.13	0.28	0.49	0.82	2.84	0.15	0.59
PC 33:1; [M-Ac-H]-@6.58	ME184570	0.14	1.51	0.49	1.56	0.12	2.54	0.51	1.28
PC 44:5; [M-Ac-H]-@8.28	ME184653	0.22	1.14	0.61	1.61	0.20	2.51	0.50	1.25
lysoPE 16:1; [M-H]-@1.17	ME184854	0.36	1.60	0.08	1.37	0.40	3.16	0.07	1.72
lysoPE 22:0; [M-H]-@4.35	ME184867	0.13	1.55	0.19	1.58	0.08	3.37	0.21	1.47
PC 42:5; [M-Ac-H]-@7.61	ME184637	0.18	1.58	1.29	0.60	0.23	3.30	1.11	0.37
PC 41:6; [M-Ac-H]-@7.27	ME184630	0.36	1.80	0.80	0.58	0.54	3.11	1.13	0.59
PC 42:9; [M-Ac-H]-@6.09	ME184642	0.33	1.78	0.89	0.79	0.33	2.80	0.87	0.82
PE 43:4; [M-H]-@8.36	ME184741	0.71	2.23	0.56	0.66	0.74	3.64	0.65	0.47
PI 36:4; [M-H]-@5.08	ME184792	0.13	2.60	0.97	0.31	0.14	3.79	1.05	0.34
PS 42:8; [M-H]-@5.39	ME184843	0.15	2.68	1.04	0.36	0.15	3.33	1.12	0.33
PC 42:7; [M-Ac-H]-@6.98	ME184640	0.15	1.95	0.98	0.62	0.24	3.61	0.92	0.50
PC 42:10; [M-Ac-H]-@5.79	ME184632	0.40	2.50	0.79	0.62	0.39	3.43	0.75	0.47
PS 36:1; [M-H]-@4.97	ME184812	0.16	2.33	0.75	0.77	0.23	3.62	0.74	0.57
lysoPE 20:1; [M-H]-@2.59	ME184862	0.19	1.95	0.07	0.77	0.32	4.69	0.15	1.44
PC 37:1; [M-Ac-H]-@7.93	ME184597	0.08	1.87	0.41	1.41	0.12	3.65	0.49	0.83
PI 40:4; [M-H]-@6.12	ME184799	NA	1.53	0.28	0.78	NA	3.93	0.35	0.86
PC 40:3; [M-Ac-H]-@7.75	ME184621	0.16	1.74	0.40	1.19	0.25	4.41	0.38	0.75
PE 39:1; [M-H]-@7.57	ME184713	0.27	1.80	0.62	1.09	0.21	4.16	0.41	0.66
PC 38:2; [M-Ac-H]-@7.67	ME184603	0.18	2.53	0.54	0.61	0.21	4.68	0.63	0.42
PC 40:4; [M-Ac-H]-@7.51	ME184622	0.20	2.24	0.76	0.56	0.26	4.52	0.75	0.33
PI 35:2; [M-H]-@5.43	ME184788	0.36	2.79	0.37	0.84	0.54	3.97	0.40	0.56
lysoPE 20:0; [M-H]-@3.40	ME184861	0.24	2.43	0.66	0.66	0.48	4.10	0.40	0.66
PI 40:5; [M-H]-@5.83	ME184800	0.24	2.33	0.44	0.76	0.49	4.22	0.51	0.65
PC 38:7; [M-Ac-H]-@5.61	ME184610	0.28	2.39	0.09	2.19	0.29	2.47	0.10	0.91
lysoPE 24:0; [M-H]-@5.28	ME184872	0.08	2.66	0.12	1.86	0.09	1.81	0.11	1.59
PC 46:4; [M-Ac-H]-@9.34	ME184657	0.10	2.79	0.08	1.63	0.13	2.46	0.07	1.48
FFA(22:0)	ME184519	0.49	2.26	0.23	1.28	0.36	2.81	0.22	1.31
lysoPE 14:0; [M-H]-@1.12	ME184851	0.41	2.20	0.70	0.95	0.44	2.48	0.22	1.37
FFA(24:3)	ME184526	0.51	3.23	0.28	1.14	0.67	2.71	0.36	0.65
PI 38:3; [M-H]-@5.97	ME184794	0.18	3.18	0.22	0.99	0.56	2.83	0.22	1.20
FFA(24:2)	ME184525	0.65	3.12	0.05	1.28	0.61	2.75	0.06	1.04
PC 40:8; [M-Ac-H]-@5.84	ME184627	0.45	2.87	0.18	1.18	0.63	2.64	0.21	1.14
plasmenyl-PE 42:4; [M-H]-@8.11	ME184910	0.11	2.68	0.72	0.98	0.12	2.21	0.80	0.94
PA 40:2; [M-H]-@7.13	ME184550	0.52	3.00	0.77	0.73	0.30	2.84	0.64	0.53
CerP 34:1; [M-H]-@5.90	ME184510	0.14	2.95	0.68	0.95	0.10	3.01	0.44	0.83
PC 37:6; [M-Ac-H]-@5.86	ME184601	0.36	2.75	0.54	0.95	0.34	2.63	0.60	0.87
PI 34:2; [M-H]-@5.12	ME184787	0.22	2.83	0.35	1.11	0.19	3.65	0.31	0.79
lysoPE 17:1; [M-H]-@1.48	ME184856	0.24	3.51	0.11	0.72	0.24	4.00	0.12	1.05
FFA(24:1)	ME184524	0.32	3.10	0.04	1.00	0.32	3.87	0.04	1.13
PI 36:2; [M-H]-@5.77	ME184790	0.19	3.21	0.09	1.15	0.15	3.78	0.11	0.98
PC 38:6; [M-Ac-H]-@6.17	ME184608	0.81	3.23	0.72	0.31	0.93	3.06	0.75	0.21
PC 39:5; [M-Ac-H]-@6.64	ME184613	0.65	3.44	0.43	0.51	0.83	3.41	0.37	0.52
PE 37:5; [M-H]-@5.93	ME184699	0.83	3.70	0.39	0.60	0.70	3.06	0.34	0.53
plasmenyl-PE 40:3; [M-H]-@8.03	ME184904	0.14	3.58	1.07	0.33	0.15	2.47	1.19	0.24
plasmenyl-PE 42:5; [M-H]-@7.90	ME184911	0.13	3.40	0.94	0.50	0.13	2.61	1.06	0.36
PI 38:5; [M-H]-@5.25	ME184796	0.23	2.74	1.10	0.37	0.20	2.82	1.19	0.34
CL 76:8; [M-2H](2-)@9.35	ME184503	0.45	2.57	1.25	0.25	0.52	2.69	1.19	0.20
PC 40:7; [M-Ac-H]-@6.30	ME184626	0.43	2.81	1.07	0.47	0.45	2.47	1.07	0.31
PC 40:5; [M-Ac-H]-@7.07	ME184624	0.21	3.05	1.37	0.16	0.27	2.43	1.38	0.12
IS PC 34:0;[M-Ac-H]-	ME184527	0.16	2.66	1.47	0.12	0.15	2.80	1.46	0.07
PC 34:0; [M-Ac-H]-@7.43	ME184573	0.16	2.67	1.47	0.12	0.15	2.79	1.45	0.07
PG 38:2; [M-H]-@6.48	ME184766	0.42	2.04	0.66	NA	0.40	1.91	0.95	NA
PG 38:3; [M-H]-@6.02	ME184767	0.49	2.10	1.33	0.42	0.39	1.58	1.56	0.42
plasmenyl-PE 38:3; [M-H]-@7.56	ME184897	0.50	2.36	1.29	0.61	0.37	1.64	1.19	0.48
PC 40:6; [M-Ac-H]-@6.80	ME184625	0.18	2.81	1.64	0.10	0.28	1.91	1.60	0.07
plasmenyl-PE 42:6; [M-H]-@7.75	ME184912	0.17	2.58	1.47	0.33	0.30	1.94	1.47	0.24
PE 39:6; [M-H]-@6.59	ME184716	0.48	3.13	1.42	0.22	0.58	1.32	1.49	0.11
plasmenyl-PE 32:0; [M-H]-@7.11	ME184876	0.46	2.93	1.19	0.46	0.23	1.20	1.61	0.34
PS 34:0; [M-H]-@6.34	ME184805	0.51	2.84	1.38	0.32	0.36	1.36	1.52	0.25
PC 34:5; [M-Ac-H]-@5.21	ME184581	0.58	0.85	NA	NA	0.79	1.77	NA	NA
PC 36:6; [M-Ac-H]-@5.47	ME184596	0.28	1.42	NA	NA	0.37	1.94	NA	NA
plasmenyl-PE 36:5; [M-H]-@6.24	ME184892	0.66	1.05	0.94	0.89	0.69	2.52	1.25	0.47
PS 46:10; [M-H]-@5.73	ME184849	0.58	1.83	0.83	0.59	1.36	2.81	0.80	0.49
PG 30:0; [M-H]-@5.00	ME184749	0.45	1.58	0.90	0.50	1.12	2.83	1.18	0.43
PC 42:11; [M-Ac-H]-@5.37	ME184633	0.50	1.59	1.09	0.51	1.18	2.45	1.12	0.43
PI 40:6; [M-H]-@5.63	ME184801	0.58	1.68	0.92	0.54	1.32	2.45	1.04	0.49
PC 35:5; [M-Ac-H]-@5.64	ME184587	1.52	1.70	0.39	NA	1.46	2.08	0.22	NA
PC 40:0; [M-Ac-H]-@9.28	ME184617	1.04	1.45	0.39	NA	1.35	2.50	0.44	NA
PG 40:9; [M-H]-@4.12	ME184778	1.79	2.51	0.52	0.60	1.57	2.37	0.38	0.39
PG 42:8; [M-H]-@5.12	ME184781	1.08	2.43	0.64	0.62	1.31	2.13	0.72	0.54

Factors:

F1	CONTROL_DIABETIC:db/db diabetic \| Sample type:Kidney
F2	CONTROL_DIABETIC:db/db diabetic \| Sample type:Plasma
F3	CONTROL_DIABETIC:db/db diabetic \| Sample type:Retina
F4	CONTROL_DIABETIC:db/db diabetic \| Sample type:Sciatic Nerve
F5	CONTROL_DIABETIC:db/m control \| Sample type:Kidney
F6	CONTROL_DIABETIC:db/m control \| Sample type:Plasma
F7	CONTROL_DIABETIC:db/m control \| Sample type:Retina
F8	CONTROL_DIABETIC:db/m control \| Sample type:Sciatic Nerve

Data matrix